Objetivo Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been higher and the growing proportion of drug-resistant TB is threatening control strategies both in the developing and developed world, Eastern Europe being a particularly worrying point in case. The anTBiotic consortium aims to fuel the long-term TB clinical pipeline while immediately offering new options to clinicians when confronted with multidrug-resistant (MDR)-TB. More specifically, the proposed studies aim to: a) Establish the proof of concept of anti-TB efficacy in humans of a pioneering, first-in-class, low-dose GSK oxaborole clinical drug candidate; b) Identify a combination of β-lactam antibiotics suitable for the treatment of MDR TB orally or as a once daily intravenous or intramuscular application and c) Incorporate the best β-lactam combination into an explorative salvage regimen for untreatable patients with extensively drug-resistant TB The anti-TB activity in humans will be established in a two-week EBA clinical studies that combine established (CFU, TTP) and new clinical markers (biomarkers, PET/CT). These datasets will help ascertain anti-TB efficacy in humans and generate confidence on their validity in longer-term drug combination trials. A variety of modelling approaches to predict optimal dosing will be used. Finally, we intend to use at least one of these novel anti-TB entities as part of a pioneering, non-controlled clinical trial in highly drug resistant subjects in Europe and South Africa. This final clinical intervention will hopefully be of immediate benefit to drug-resistant patients in the EU and elsewhere in addition to generating a strong precedent for further adoption worldwide. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesclinical medicinepneumologytuberculosismedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance Palabras clave Tuberculosis Programa(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Tema(s) SC1-PM-09-2016 - New therapies for chronic diseases Convocatoria de propuestas H2020-SC1-2016-2017 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SC1-2016-RTD Régimen de financiación RIA - Research and Innovation action Coordinador GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL Aportación neta de la UEn € 704 870,67 Dirección C/ SEVERO OCHOA NUMERO 2 PARQUE TECNOLOGICO DE MAD 28760 TRES CANTOS MADRID España Ver en el mapa Región Comunidad de Madrid Comunidad de Madrid Madrid Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 704 870,67 Participantes (4) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET Noruega Aportación neta de la UEn € 644 072,50 Dirección HANSINE HANSENS VEG 14 9019 Tromso Ver en el mapa Región Norge Nord-Norge Troms og Finnmark Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 644 072,50 FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM Alemania Aportación neta de la UEn € 1 242 417,00 Dirección PARKALLEE 1-40 23845 Borstel Ver en el mapa Región Schleswig-Holstein Schleswig-Holstein Segeberg Tipo de actividad Research Organisations Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 1 242 417,00 UNIVERSITY OF CAPE TOWN Sudáfrica Aportación neta de la UEn € 209 953,75 Dirección PRIVATE BAG X3 7701 Rondebosch Ver en el mapa Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 209 953,75 TASK FOUNDATION NPC Sudáfrica Aportación neta de la UEn € 3 018 102,08 Dirección M2 KARL BREMER HOSPITAL MIKE PIENAAR BOULEVARD BELLEVILLE 7530 Cape Town Ver en el mapa Tipo de actividad Other Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 3 018 102,08